Focus Investment Banking

SEPTEMBER 24, 2024

I don’t know what goes on in those because I haven’t crashed one yet, but I’m imagining free food and drink and listening to a firm’s pitch. The cocktail reception features an open bar and carving/food stations and is usually followed by an awards show and ceremony. The focus here is on publicly traded companies. Where we stay.

Food 52

Food Retail Investment Banking Business 52

Focus Investment Banking

JANUARY 10, 2025

Now say we’re in good fortune here for this example because there is only one Pureplay Collision Group that is publicly traded and we know them as the Boy Group or Gerber Collision and Glass. Because they’re publicly traded, we get access to their financials and see how they do quarter in and quarter out and annually for 2023.

Private Equity 52

Private Equity Mergers and Acquisitions M&A Equities 52

Mergers and Inquisitions

JANUARY 8, 2025

Being in your country’s top ~5% of earners will make a FAR bigger difference than fancy strategies, day trading, or finding the occasional meme coin that goes up by 100x. Active Trading: I do not recommend day trading unless it is your full-time job. Yes, you will spend more money on rent, food, vacations, etc.,

Investment 59

Investment Portfolio S&P Trading 59

Focus Investment Banking

FEBRUARY 11, 2025

Overcoming Marketplace Uncertainty Rising interest rates introduced a difficult environment for private equity recapitalizations (where private equity groups sell a portfolio company to another buyer), so few of the older PE-backed ophthalmology organizations traded hands over the last few years. The theme is not entirely new, however.

Private Equity 52

Private Equity Healthcare Equities Medical 52

Cooley M&A

JANUARY 22, 2025

Public company deals: Smaller bites in more focused therapeutic areas The landscape for public company sales in the life sciences sector in 2024 was notably quieter than expected, with anticipated high-profile deals failing to materialize.

M&A 64

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 64